<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23358" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Immunoglobulin E</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Godwin</surname>
            <given-names>Luke</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sinawe</surname>
            <given-names>Hadeer</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Crane</surname>
            <given-names>Jonathan S.</given-names>
          </name>
          <aff>Sampson Regional Med Ctr / Campbell Univ</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Luke Godwin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hadeer Sinawe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Crane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23358.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Immunoglobulin E is&#x000a0;1 of the 5 classes of immunoglobulins (IgM, IgG, IgD, IgA, IgE). IgE has a unique chemical structure and various physiological functions, such as type I hypersensitivity reactions, parasitic infections, autoimmune processes, and venom protection.<xref ref-type="bibr" rid="article-23358.r1">[1]</xref>&#x000a0;It was the last of the immunoglobulin family to be discovered. Since then, it has spurred vast research to characterize its&#x000a0;biochemistry and&#x000a0;role in disease processes. Technological advancements have also been used to evaluate patient IgE levels and new pharmacological therapies that may inhibit its function altogether.<xref ref-type="bibr" rid="article-23358.r2">[2]</xref>&#x000a0;The following&#x000a0;article aims to provide an overview detailing the biochemical structure and function of IgE, as well as some examples of its clinical implications.</p>
      </sec>
      <sec id="article-23358.s2" sec-type="Molecular Level&#x0000d;&#x0000a;">
        <title>Molecular Level
</title>
        <p>All immunoglobulin molecules have a common structural framework characterized by&#x000a0;2 identical small polypeptide chains (light chains) and&#x000a0;2 identical large polypeptide chains (heavy chains). The fragment crystallizable (Fc) region of the antibody is comprised solely of the&#x000a0;2 heavy chains and is responsible for binding to cellular receptors. The fragment antigen-binding (Fab) region of the antibody is where antigen recognition and binding occur and is made up of&#x000a0;2 heavy chains continuous with the Fc region and&#x000a0;2 light chains. These chains also have variable and constant regions. At the antigen binding sites, both polypeptide chains contain variable regions whose amino acid sequences can be altered for affinity maturation to occur for a given antigen. The variable heavy (VH) and variabl light (VL) chains are organized into layers of antiparallel B-pleated sheets, allowing the antigen to bind between these 3-dimensional immunoglobulin folds. The rest of the polypeptide regions are known as constant regions, and they are held together by strong dipeptide bonds to stabilize the&#x000a0;2 chains.<xref ref-type="bibr" rid="article-23358.r3">[3]</xref></p>
        <p>Some antibodies, like IgM, can have&#x000a0;5 duplicates of the structure above to form a pentamer capable of binding up to ten antigens. However, IgE is a monomer composed of&#x000a0;2 epsilon-heavy chains and&#x000a0;2 light chains, thus capable of binding a total of&#x000a0;2 antigens, which occurs through the variable regions of the light and heavy chains that create unique antigen-specific binding sites. The C-terminal regions of the heavy chains are composed of&#x000a0;4 C-epsilon dimers, C-epsilon 1-4.<xref ref-type="bibr" rid="article-23358.r4">[4]</xref> The chemical structure of these dimers is essential for binding IgE-specific cellular receptors Fc-epsilon RI and CD23, which will be discussed in more detail later. Some immunoglobulins, such as IgG, contain a "hinge" region near the molecule's center. IgE is unique because it lacks this hinge region and is replaced by the C-epsilon2 domain. There is a theory that the lack of this hinge region allows the IgE molecule to adopt a more flexible conformation while interacting with its receptors. Furthermore, the IgE molecule is more heavily glycosylated than&#x000a0;other antibodies, containing 7 N-linked glycosylations on each heavy chain, which is necessary for binding to a high-affinity cellular receptor, Fc-epsilon-RI (see <bold>Diagram.</bold>&#x000a0;Basic Unit of Immunoglobulin [Antibody]).<xref ref-type="bibr" rid="article-23358.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23358.s3" sec-type="Function">
        <title>Function</title>
        <p>The biochemical considerations mentioned determine the structure of IgE and drive the function of allowing IgE to bind to given antigens and IgE-specific cellular receptors. For IgE to accomplish its function, the Fc portion of the antibody must bind to a given cellular receptor located on a particular type of cell, such as a mast cell, eosinophil, etc. Although many cellular receptors have been identified and studied, the main ones are Fc-epsilon-RI and Fc-epsilon-RII, or CD23.&#x000a0;<xref ref-type="bibr" rid="article-23358.r5">[5]</xref>&#x000a0;Fc-epsilon-RI, or the high-affinity receptor, is mainly located on mast cells, basophils, dendritic cells, macrophages, and eosinophils. It is thus responsible for immediate hypersensitivity reactions, parasitic immunity, enhanced cytokine production, and antigen presentation. The other receptor, CD23, or the low-affinity receptor, is primarily expressed on B-cells, T-cells, and antigen-presenting cells (APCs) and is responsible for IgE production homeostasis, facilitated antigen presentation (FAP), as well as transportation of IgE across airway and gut epithelia.<xref ref-type="bibr" rid="article-23358.r6">[6]</xref></p>
      </sec>
      <sec id="article-23358.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The role of IgE is central in allergy sensitization and atopic disorders such as allergic rhinitis, asthma, and atopic dermatitis. These disorders manifest due to type I hypersensitivity reactions involving IgE and other immune cells to produce the clinical symptoms seen in those disorders ultimately. It starts with an initial exposure to an antigen or allergen, which is taken up and processed by a dendritic cell or macrophage, which presents the antigen to a T-cell. In the presence of cytokine mediators IL-4 and IL-13, these T-cells are induced to differentiate into TH2 helper T-cells capable of presenting the antigen to B-cells.<xref ref-type="bibr" rid="article-23358.r6">[6]</xref> The B-cells then undergo class-switching recombination events to produce Immunoglobulin E antibodies capable of binding to the presented antigen at the "antigen binding site" of the Fab portion of the antibody. Once this initial sensitization to antigen has occurred, more immunological events can ensure a more robust IgE response. The CD23 receptor on intestinal or airway epithelial cells can transport antigen-IgE complexes across the epithelium to bind Fc-epsilon-RI receptors on mast cells, macrophages, and other immune cells to promote inflammation, cytokine production, and more local IgE production. Furthermore, via interaction with the CD23 receptor on B-cells and myeloid cells, a process known as FAP can occur.</p>
        <p>FAP involves antigen-IgE complexes binding to CD23 receptors on B-cells, which then present the peptides to T-cells to facilitate further IgE antibody production.&#x000a0;<xref ref-type="bibr" rid="article-23358.r7">[7]</xref>&#x000a0;This approach contrasts with the classical antigen presentation pathway described above. Instead of T-cells being the primary antigen presenters to the B-cell, it is now antigen-IgE complexes formed in the periphery, which may or may not be related to the initial antigen. This has clinical importance because, via facilitated antigen presentation, the B-cells will ultimately present a diverse array of peptides to T-cells to clear it for further immunoglobulin production. In conclusion, this is a mechanism for epitope spreading, where an antibody response for&#x000a0;1 antigen can cause the production of antibodies to different antigens.<xref ref-type="bibr" rid="article-23358.r6">[6]</xref> This could be why individuals can develop allergies to multiple antigens resulting in a phenomenon known as "atopic march."<xref ref-type="bibr" rid="article-23358.r8">[8]</xref> For example, a child could have atopic dermatitis and later in life develop asthma. In conclusion, facilitated antigen presentation produces a more robust immune response to a given antigenic exposure that could be responsible for sensitization to multiple unrelated antigens.&#x000a0;</p>
        <p>Once initial exposure to an antigen has occurred, and an immune response has been activated, antigen-specific IgE will remain bound via the Fc-epsilon RI receptor to mast cells and basophils. It has been shown that binding alone of IgE to that receptor cause IgE-dependent upregulation of mast cell Fc-epsilon RI receptor expression, which allows these cells to bind more IgE antibodies.<xref ref-type="bibr" rid="article-23358.r6">[6]</xref> Furthermore, it is essential to note that IgE has a short half-life in plasma, usually less than a day. However, IgE bound to a high-affinity receptor (Fc-epsilon RI) can remain attached to mast cells in tissues for weeks to months.<xref ref-type="bibr" rid="article-23358.r4">[4]</xref> Later, upon re-exposure to a given antigen, crosslinking of adjacent Fc-epsilon RI-bound IgE antibodies occurs and binds the antigen, which causes subsequent aggregation of Fc-epsilon RI receptors. Once this happens and there is a sufficient aggregation of these receptors with bound antigen, it causes mast cells and basophils to release preformed chemical mediators stored in cytoplasmic granules such as histamine, serotonin, tryptase, prostaglandins, leukotrienes, and eosinophil or neutrophil chemotactic factors.<xref ref-type="bibr" rid="article-23358.r6">[6]</xref></p>
      </sec>
      <sec id="article-23358.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>It is essential to note that not everyone exposed to environmental antigens will generate a strong immune reaction described above. Certain people, known as "atopics," have a genetic predisposition for developing type&#x000a0;I&#x000a0;hypersensitivity responses to antigens in the environment. Clinically, the manifestations of this type one hypersensitivity reaction are usually due to the actions of the released chemical mediators such as histamine, leukotrienes, and other cytokines. Histamine release causes increased vascular permeability, smooth muscle constriction, and mucus secretion. Leukotrienes B4, C4, D4, and E4 are also often secreted and responsible for chemotaxis, inflammation, and anaphylaxis. Furthermore, if in enough quantity, histamine and other mediators can cause systemic vascular effects such as vasodilation and increased vessel permeability, causing hypotension and edema.<xref ref-type="bibr" rid="article-23358.r6">[6]</xref> This could lead to anaphylactic shock and death if severe and poorly managed.&#x000a0;</p>
        <p>The manifestations can occur in many different areas of the body. Involvement of the upper airway can cause many patients to suffer from mild seasonal allergies or allergic rhinitis. Due to repeated inhalation exposure to pollen and other outdoor antigens, type&#x000a0;I&#x000a0;hypersensitivity occurs, and mast cell degranulation causes epiphora, rhinorrhea, cough, and other symptoms. Additionally, the involvement of the lower airway in patients with atopic asthma experiences an immune response to aeroallergens resulting in airway smooth muscle constriction, increased mucus production and inflammation that manifests as obstructive lung disease. The skin can often be involved, and due to vasodilation and dermal edema, urticaria or "wheals&#x02019;"can be evident.<xref ref-type="bibr" rid="article-23358.r9">[9]</xref></p>
        <p>Another skin disease that has been studied concerning the roles of IgE and hypersensitivity is atopic dermatitis or eczema. Although eczema is a multifactorial disease involving genetics, barrier dysfunction, and immune dysregulation, some evidence suggests IgE-mediated hypersensitivity may also play a role.<xref ref-type="bibr" rid="article-23358.r10">[10]</xref> The inflammatory infiltrates of AE lesions are composed mainly of CD4+ helper T-cells, with a predominance of TH2 cells, which are responsible for initiating IgE class switching by B-cells. Certain aeroallergens were found to penetrate compromised skin in eczema patients and interact with Langerhans cells. Furthermore, these same cells were discovered to have IgE binding structures on their surface.<xref ref-type="bibr" rid="article-23358.r11">[11]</xref>&#x000a0;A correlation has also revealed that up to 80% to 85% of patients with atopic dermatitis have elevated IgE levels.<xref ref-type="bibr" rid="article-23358.r12">[12]</xref> One study even conducted atopy patch tests on eczema patients and correlated their allergen-specific serum IgE. It showed that most patients (40%, N=151) with positive atopy patch test for <italic toggle="yes">D. pteronyssinus</italic> (house dust allergen) also had elevated serum IgE specific for that antigen. This study also demonstrated that there were patients (9%) with a positive atopy patch test and no elevation in serum IgE, in addition to other patients with a negative patch test.<xref ref-type="bibr" rid="article-23358.r11">[11]</xref> Thus, given the known multifactorial nature of atopic dermatitis, it is likely that some correlation may exist between IgE-mediated hypersensitivity and eczema. However, the exact nature of this relationship requires further investigation.</p>
        <p>IgE has also been implicated in the defense against parasitic organisms such as helminths. Helminthic infections are usually the result of soil transmission and infect up to one-third of people worldwide.<xref ref-type="bibr" rid="article-23358.r13">[13]</xref> When the immune system encounters this type of parasite, the B-cell class switch to IgE antibodies, which then "coat" the parasite via binding many antibodies. Following this, effector cells such as eosinophils and mast cells recognize Immunoglobulin E bound to the helminth and can then attach the Fc portion of the antibody via the Fc-epsilon RI receptor. Once connected, subsequent reactions occur, such as further cytokine release and histamine production by mast cells, as well as major essential protein and eosinophil peroxidase production by eosinophils.<xref ref-type="bibr" rid="article-23358.r14">[14]</xref> These substances are toxic to the helminth and can thus result in parasitic killing and the ultimate clearance of the invader.&#x000a0;</p>
        <p>As depicted in this article, Immunoglobulin E has a specific biochemical structure and function that guides its unique role in disease processes such as type I hypersensitivity reactions, helminthic infections, and more. The research in the past 50 years regarding IgE has established a better&#x000a0;idea of its role in disease. Not only has this aided in a more in-depth clinical understanding of IgE-related health disorders, but it has even spurred novel treatment modalities. A humanized monoclonal antibody named omalizumab has been engineered, which targets the IgE antibody, thus rendering it ineffective in producing associated symptoms. This drug has been shown to provide benefits and relief in patients with moderate to severe asthma and intermittent and persistent allergic rhinitis.<xref ref-type="bibr" rid="article-23358.r15">[15]</xref> Despite this progress, much more remains to be learned about the exact function of this immunoglobulin in those diseases in which some correlation has already been established, as well as novel clinical&#x000a0;relationships yet to be discovered.&#x000a0;</p>
      </sec>
      <sec id="article-23358.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23358&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23358">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23358/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23358">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23358.s7">
        <fig id="article-23358.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Basic Unit of Immunoglobulin (Antibody). 1. Fab region; 2. Fc region; 3. Heavy chains (consist of VH, CH1, hinge, CH2, and CH3 regions from the N-terminus); 4. Light chains (consist of VL and CL regions from the N-terminus); 5. Antigen binding site; 6. Hinge regions. Y Tambe, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-sa/3.0/deed.en">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Immunoglobulin__basic__unit" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23358.s8">
        <title>References</title>
        <ref id="article-23358.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutton</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Karagiannis</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>IgE Antibodies: From Structure to Function and Clinical Translation.</article-title>
            <source>Antibodies (Basel)</source>
            <year>2019</year>
            <month>Feb</month>
            <day>22</day>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31544825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansotegui</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Melioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Caraballo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ebisawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Passalacqua</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Savi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ebo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Luengo S&#x000e1;nchez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Jensen-Jarolim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Haahtela</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Antila</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bousquet</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Demoly</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>DuBuske</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Ferrer Puga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gerth van Wijk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez D&#x000ed;az</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Gonzalez-Estrada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jares</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalpaklio&#x0011f;lu</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Kase Tanno</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Monge Ortega</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Morais Almeida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Pawankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Renz</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Ros&#x000e1;rio Filho</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rosenwasser</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Borges</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Scala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Senna</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Sisul</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>MLK</given-names>
              </name>
              <name>
                <surname>Thong</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Valenta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Zuberbier</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper.</article-title>
            <source>World Allergy Organ J</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>100080</fpage>
            <pub-id pub-id-type="pmid">32128023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schroeder</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Cavacini</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of immunoglobulins.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>125</volume>
            <issue>2 Suppl 2</issue>
            <fpage>S41</fpage>
            <page-range>S41-52</page-range>
            <pub-id pub-id-type="pmid">20176268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oettgen</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>137</volume>
            <issue>6</issue>
            <fpage>1631</fpage>
            <page-range>1631-1645</page-range>
            <pub-id pub-id-type="pmid">27263999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poole</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rosenwasser</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis.</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2005</year>
            <month>May</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>252</fpage>
            <page-range>252-8</page-range>
            <pub-id pub-id-type="pmid">15842964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galli</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>IgE and mast cells in allergic disease.</article-title>
            <source>Nat Med</source>
            <year>2012</year>
            <month>May</month>
            <day>04</day>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>693</fpage>
            <page-range>693-704</page-range>
            <pub-id pub-id-type="pmid">22561833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilcock</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2006</year>
            <month>May</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>333</fpage>
            <page-range>333-47, viii-ix</page-range>
            <pub-id pub-id-type="pmid">16701148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amarasekera</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin E in health and disease.</article-title>
            <source>Asia Pac Allergy</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-5</page-range>
            <pub-id pub-id-type="pmid">22053291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Vashisht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zito</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <chapter-title>Immediate Hypersensitivity Reactions</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30020687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomsen</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Atopic dermatitis: natural history, diagnosis, and treatment.</article-title>
            <source>ISRN Allergy</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>354250</fpage>
            <pub-id pub-id-type="pmid">25006501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darsow</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin e-mediated allergy plays a role in atopic eczema as shown in the atopy patch test.</article-title>
            <source>World Allergy Organ J</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">23283386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Goodarzi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HY</given-names>
              </name>
            </person-group>
            <article-title>IgE, mast cells, and eosinophils in atopic dermatitis.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>298</fpage>
            <page-range>298-310</page-range>
            <pub-id pub-id-type="pmid">21249468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McSorley</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Maizels</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Helminth infections and host immune regulation.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <page-range>585-608</page-range>
            <pub-id pub-id-type="pmid">23034321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anthony</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rutitzky</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Stadecker</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gause</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Protective immune mechanisms in helminth infection.</article-title>
            <source>Nat Rev Immunol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>975</fpage>
            <page-range>975-87</page-range>
            <pub-id pub-id-type="pmid">18007680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23358.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Grayson</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin E, what is it good for?</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-7</page-range>
            <pub-id pub-id-type="pmid">26945494</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
